{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Topotecan+Hydrochloride&page=13", "query": { "intervention": "Topotecan Hydrochloride", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 329, "total_pages": 33, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Topotecan+Hydrochloride&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Topotecan+Hydrochloride&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T15:26:03.425Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06666712", "title": "Chronic CED of TPT for Recurrent Malignant Glioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Tumor, Recurrent", "Malignant Glioma (WHO Grade III or IV)", "IDH1/IDH2 Mutation" ], "interventions": [ { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jeffrey N. Bruce", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2026-06-12", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-10-19T15:26:03.425Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06666712" }, { "nct_id": "NCT04239092", "title": "9-ING-41 in Pediatric Patients With Refractory Malignancies.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Cancer", "Refractory Neoplasm", "Cancer Pediatric", "Refractory Tumor", "Pediatric Cancer", "Pediatric Brain Tumor", "Neuroblastoma", "Neuroblastoma Recurrent", "Pediatric Lymphoma", "Pediatric Meningioma", "Diffuse Intrinsic Pontine Glioma" ], "interventions": [ { "name": "9-ING-41", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actuate Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "22 Years", "sex": "ALL", "summary": "Up to 22 Years" }, "enrollment_count": 40, "start_date": "2020-06-05", "completion_date": "2025-07-07", "has_results": false, "last_update_posted_date": "2025-07-17", "last_synced_at": "2026-10-19T15:26:03.425Z", "location_count": 9, "location_summary": "San Francisco, California • Aurora, Colorado • Chicago, Illinois + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04239092" }, { "nct_id": "NCT00259935", "title": "A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer, Small Cell" ], "interventions": [ { "name": "topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2004-10-04", "completion_date": "2007-07-05", "has_results": false, "last_update_posted_date": "2017-11-14", "last_synced_at": "2026-10-19T15:26:03.425Z", "location_count": 6, "location_summary": "Lebanon, New Hampshire • The Bronx, New York • Philadelphia, Pennsylvania + 3 more", "locations": [ { "city": "Lebanon", "state": "New Hampshire" }, { "city": "The Bronx", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00259935" }, { "nct_id": "NCT03236857", "title": "A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignancies", "Acute Lymphoblastic Leukemia (ALL)", "Acute Myeloid Leukemia (AML)", "Non-Hodgkin's Lymphoma", "Neuroblastoma" ], "interventions": [ { "name": "chemotherapy", "type": "DRUG" }, { "name": "venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "0 Years to 25 Years" }, "enrollment_count": 143, "start_date": "2017-11-08", "completion_date": "2023-04-19", "has_results": false, "last_update_posted_date": "2023-05-22", "last_synced_at": "2026-10-19T15:26:03.425Z", "location_count": 11, "location_summary": "San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 8 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03236857" }, { "nct_id": "NCT02354547", "title": "A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm" ], "interventions": [ { "name": "SGT-53", "type": "GENETIC" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "SynerGene Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 18, "start_date": "2014-12", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-19T15:26:03.425Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02354547" }, { "nct_id": "NCT06172296", "title": "Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ganglioneuroblastoma, Nodular", "Neuroblastoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dinutuximab", "type": "BIOLOGICAL" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "FDG-Positron Emission Tomography and Computed Tomography Scan", "type": "PROCEDURE" }, { "name": "Hematopoietic Cell Transplantation", "type": "PROCEDURE" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Isotretinoin", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Tumor Resection", "type": "PROCEDURE" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 478, "start_date": "2024-04-19", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-19T15:26:03.425Z", "location_count": 157, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 127 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06172296" }, { "nct_id": "NCT04661852", "title": "Cabozantinib With Topotecan-Cyclophosphamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Ewing Sarcoma", "Refractory Ewing Sarcoma", "Relapsed Osteosarcoma", "Refractory Osteosarcoma" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Myeloid growth factor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "6 Years to 30 Years" }, "enrollment_count": 12, "start_date": "2020-12-23", "completion_date": "2022-10-24", "has_results": false, "last_update_posted_date": "2023-02-15", "last_synced_at": "2026-10-19T15:26:03.425Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04661852" }, { "nct_id": "NCT00002814", "title": "Combination Chemotherapy for Patients With Brain Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "1996-08", "completion_date": "2001-12", "has_results": false, "last_update_posted_date": "2011-10-27", "last_synced_at": "2026-10-19T15:26:03.425Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002814" }, { "nct_id": "NCT01849874", "title": "A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Low-grade Serous Ovarian Cancer", "Low-grade Serous Fallopian Tube Cancer", "Low-grade Serous Peritoneal Cancer" ], "interventions": [ { "name": "MEK162, MEK inhibitor; oral", "type": "DRUG" }, { "name": "Physician's choice chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 341, "start_date": "2013-06-27", "completion_date": "2022-08-23", "has_results": true, "last_update_posted_date": "2023-10-30", "last_synced_at": "2026-10-19T15:26:03.425Z", "location_count": 77, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 37 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01849874" }, { "nct_id": "NCT00588991", "title": "Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Megakaryoblastic Leukemia", "Adult Acute Monoblastic Leukemia", "Adult Acute Monocytic Leukemia", "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With Maturation", "Adult Acute Myeloid Leukemia With Minimal Differentiation", "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1", "Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A", "Adult Acute Myeloid Leukemia Without Maturation", "Adult Acute Myelomonocytic Leukemia", "Adult Erythroleukemia", "Adult Pure Erythroid Leukemia", "Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive", "Chronic Myelomonocytic Leukemia", "De Novo Myelodysplastic Syndrome", "Essential Thrombocythemia", "Hematopoietic and Lymphoid Cell Neoplasm", "Myelodysplastic Syndrome", "Polycythemia Vera", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndrome" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2008-02-04", "completion_date": "2016-11-16", "has_results": false, "last_update_posted_date": "2025-04-02", "last_synced_at": "2026-10-19T15:26:03.425Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Rochester, Minnesota", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00588991" } ] }